A Case of Cutaneous T-cell Lymphoma, Masquerading as Psoriasis, Was Given Etanercept and Secukinumab: Emphasizing the Need for Biopsy Confirmation before Starting Biologics.
作者信息
De Abhishek, Raychaudhury Tanumay, Rajagopalan Murlidhar, Sarda Aarti, Sharma Nidhi
机构信息
Department of Dermatology, Calcutta National Medical College, Kolkata, West Bengal, India. E-mail:
Cutaneous Oncology, Tata Medical Centre, Kolkata, West Bengal, India.
出版信息
Indian J Dermatol. 2017 Sep-Oct;62(5):533-535. doi: 10.4103/ijd.IJD_311_17.
Abstract
摘要
相似文献
1
A Case of Cutaneous T-cell Lymphoma, Masquerading as Psoriasis, Was Given Etanercept and Secukinumab: Emphasizing the Need for Biopsy Confirmation before Starting Biologics.
Indian J Dermatol. 2017 Sep-Oct;62(5):533-535. doi: 10.4103/ijd.IJD_311_17.
2
Secukinumab - First in Class Interleukin-17A Inhibitor for the Treatment of Psoriasis.
Indian J Dermatol. 2017 Mar-Apr;62(2):195-199. doi: 10.4103/ijd.IJD_233_16.
3
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept.
J Am Acad Dermatol. 2017 Apr;76(4):655-661. doi: 10.1016/j.jaad.2016.11.043. Epub 2017 Jan 10.
4
Secukinumab in plaque psoriasis--results of two phase 3 trials.
N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9.
5
Secukinumab (AIN457) for the treatment of psoriasis.
Expert Rev Clin Immunol. 2015;11(11):1177-88. doi: 10.1586/1744666X.2015.1095092. Epub 2015 Oct 1.
6
Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.
Expert Rev Pharmacoecon Outcomes Res. 2016;16(2):153-66. doi: 10.1586/14737167.2016.1133301. Epub 2016 Feb 2.
7
Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.
J Am Acad Dermatol. 2016 Jul;75(1):83-98.e4. doi: 10.1016/j.jaad.2016.03.024. Epub 2016 May 12.
8
Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.
J Drugs Dermatol. 2015 Aug;14(8):821-33.
9
Sudden onset of an aggressive cutaneous lymphoma in a young patient with psoriasis: role of immunosuppressants.
Acta Derm Venereol. 2010 Nov;90(6):616-20. doi: 10.2340/00015555-0978.
10
Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis - nationwide results from the DERMBIO registry.
J Eur Acad Dermatol Venereol. 2017 Jul;31(7):1183-1187. doi: 10.1111/jdv.14200. Epub 2017 Mar 29.
引用本文的文献
1
Intra-Class Interleukin-(IL)-17 Blocker Switching: Ixekizumab as a Solution for Secukinumab Non-responders in Secondary Biologic Failure in Psoriasis.
Cureus. 2025 Feb 13;17(2):e78954. doi: 10.7759/cureus.78954. eCollection 2025 Feb.
2
Increased Risk of Cutaneous T-Cell Lymphoma Development after Dupilumab Use for Atopic Dermatitis.
Dermatol Ther. 2024 Jan;2024. doi: 10.1155/2024/9924306. Epub 2024 Aug 14.
3
Risk of Cutaneous T Cell Lymphoma with Psoriasis Biologic Therapies.
Dermatol Ther (Heidelb). 2024 Jan;14(1):15-30. doi: 10.1007/s13555-023-01074-z. Epub 2023 Dec 3.
4
Safety and danger of biologic treatments in psoriasis in context of cutaneous T-cell lymphoma (CTCL).
Postepy Dermatol Alergol. 2021 Dec;38(6):953-960. doi: 10.5114/ada.2021.107553. Epub 2021 Oct 25.
5
Gene expression profiling and immune cell-type deconvolution highlight robust disease progression and survival markers in multiple cohorts of CTCL patients.
Oncoimmunology. 2018 May 31;7(8):e1467856. doi: 10.1080/2162402X.2018.1467856. eCollection 2018.
本文引用的文献
1
Cutaneous T-Cell Lymphoma in a Patient With Psoriasis.
Am J Med Sci. 2017 Feb;353(2):193. doi: 10.1016/j.amjms.2016.05.028. Epub 2016 Jun 1.
2
Mycosis fungoides with psoriasiform lesions.
J Dermatol. 2015 Feb;42(2):227-9. doi: 10.1111/1346-8138.12749. Epub 2015 Jan 8.
3
Mycosis fungoides: an important differential diagnosis for acquired palmoplantar keratoderma.
Australas J Dermatol. 2015 Feb;56(1):49-51. doi: 10.1111/ajd.12155. Epub 2014 Feb 26.
4
Erythroderma is not all psoriasis: a case of Sézary syndrome.
Br J Hosp Med (Lond). 2014 Jan;75(1):50-1. doi: 10.12968/hmed.2014.75.1.50.
5
Sudden onset of an aggressive cutaneous lymphoma in a young patient with psoriasis: role of immunosuppressants.
Acta Derm Venereol. 2010 Nov;90(6):616-20. doi: 10.2340/00015555-0978.
6
What can psoriasis teach us about the genetic basis of cutaneous T-cell lymphoma?
Clin Lymphoma Myeloma Leuk. 2010 Sep;10 Suppl 2:S70-3. doi: 10.3816/CLML.2010.s.011.
7
Exacerbation of undiagnosed mycosis fungoides during treatment with etanercept.
Arch Dermatol. 2009 Jan;145(1):94-5. doi: 10.1001/archdermatol.2008.526.
8
Progression of undiagnosed cutaneous T-cell lymphoma during efalizumab therapy.
Arch Dermatol. 2009 Jan;145(1):92-4. doi: 10.1001/archdermatol.2008.530.
9
Histologic mimickers of mycosis fungoides: a review.
J Cutan Pathol. 2007 Jul;34(7):519-25. doi: 10.1111/j.1600-0560.2006.00662.x.
10
The risk of lymphoma in patients with psoriasis.
J Invest Dermatol. 2006 Oct;126(10):2194-201. doi: 10.1038/sj.jid.5700410. Epub 2006 Jun 1.
Zotero 插件